表紙
市場調查報告書

免疫療法藥、設備、患者實施

Immunotherapeutic Drugs, Devices & Patient Enablement

出版商 Greystone Research Associates 商品編碼 729889
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
免疫療法藥、設備、患者實施 Immunotherapeutic Drugs, Devices & Patient Enablement
出版日期: 2018年10月22日內容資訊: 英文
簡介

本報告以自我給藥免疫療法藥市場為焦點,提供朝向患者實施及自我給藥的趨勢主要要素的相關調查,適用自我給藥的已經過核准免疫療法藥為何,供給時的包裝為何,目前自我給藥免疫療法藥的市場規模,市場佔有率的領導企業與市場佔有率的預測,及免疫療法藥影響市場的經濟、技術、規定要素等相關分析。

摘要整理

市場動態

  • 競爭情形
  • 每劑量的成本、管理護理
  • 生物相似藥
  • 產品設計、實施要素
  • 人因工程/人體工學
  • 設備開發及供給時的包裝

自我給藥可能設備

  • 設備的選擇
  • 預填充式注射器
  • 自動注射器
  • 筆型注射器
  • 新的設備

自我給藥免疫療法藥的評估

治療市場區隔分析、預測

市場預測

  • 法規要素
  • 臨床實驗通訊協定 & 端點
  • 聯盟、結盟

企業簡介

目錄
Product Code: JPE479K

Drug Formulation & Packaging Migration Creating Self-Dosing Opportunities

The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.

Immunotherapeutic Drugs, Devices & Patient Enablement - What You Will Learn:

  • What approved immunotherapeutic drugs are indicated for self-administration, what is the as-supplied packaging, what are the device specifics, and who markets them?
  • What are the major factors driving the migration of infusible immunotherapeutic drugs to formulations that can be packaged and administered subcutaneously?
  • What is the size of the market for self-administered immunotherapeutic drugs today, who are the market share leaders, and what will the market share be in 2022?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the essential design factors, technologies and market development issues for devices that can deliver injectable immunotherapeutics subcutaneously?
  • What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?

Table of Contents

Executive Summary

Market Dynamics

  • Competitive Landscape
    • Biological Supply Chain Activity
    • FDA/EMA Immunotherapeutics Regulatory Overview
  • Cost per Dose and Managed Care
  • Biosimilars
  • Product Design and Enablement Factors
    • Ease of Use
    • Patient Adherence
  • Human Engineering/Ergonomics
    • Patient-centered Design
    • Patient Interface
    • Patient Preferences
  • Device Development and As-Supplied Packaging
    • Device Supplier Segment Analysis
    • Pre- and Post-marketing Device Evolution

Self-administered Enabling Devices

  • Device Selection - Stability and Materials Issues
  • Prefilled Syringes
  • Autoinjectors
    • Manual Injection Autoinjectors
    • Automatic Injection Autoinjectors
    • Special Feature Autoinjectors
    • Variable Dose Autoinjectors
  • Pen Injectors
  • Emerging Devices

Self-administered Therapeutic Autoimmune Drug Assessment

Therapeutic Market Segment Analysis & Forecasts

Market Factors

  • Regulatory Factors
  • Clinical Trial Protocols & Endpoints
  • Alliances and Partnerships

Company Profiles

Back to Top